GlassScriptPhysician profile
Erica Williams
NPI 1164207593
$6,569.16
in general payments reported to CMS, 2019-2025
27 companies · $2,930 in 2025
The $2,930 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $317 · 2024: $3,322 · 2025: $2,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,548 · Education: $21.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,547.73 |
| Education | $21.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,295.44 | 2024-2025 | |
| Janssen Biotech, INC. | $785.55 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $583.37 | 2024-2025 | |
| Madrigal Pharmaceuticals | $551.42 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $549.16 | 2024 | Voquezna |
| Ardelyx, INC. | $513.24 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $456.34 | 2024-2025 | Vowst, Zenpep |
| Gilead Sciences, INC. | $240.17 | 2024 | Vemlidy, Livdelzi |
| Regeneron Healthcare Solutions, INC. | $201.39 | 2024-2025 | Dupixent |
| Celltrion USA INC. | $170.00 | 2024-2025 | Zymfentra, Vegzelma |
| Ipsen Biopharmaceuticals, INC | $163.62 | 2024-2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.86 | 2024-2025 | Trulance, Relistor, Xifaxan |
| Novo Nordisk INC | $143.39 | 2023-2025 | Ozempic |
| Pfizer INC. | $140.87 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $129.23 | 2023 | Zeposia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $91.45 | 2023-2025 | |
| Albireo Pharma, INC. | $66.64 | 2024 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $66.48 | 2023-2024 | Entyvio, Gattex |
| Intercept Pharmaceuticals, INC. | $61.60 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $43.18 | 2024 | Clenpiq |
| Lilly USA, LLC | $33.48 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $29.95 | 2025 | Sucraid |
| Neurocrine Biosciences, INC. | $26.45 | 2024 | Ingrezza |
| Boston Scientific Corporation | $24.63 | 2024 | Watchman Flx |
| Mirum Pharmaceuticals, INC. | $22.20 | 2024 | Livmarli |
| Braintree Laboratories, INC. | $20.57 | 2024 | Suflave, Sutab |
| Exact Sciences Corporation | $14.48 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.